This company has been marked as potentially delisted and may not be actively trading. Viela Bio (VIE) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock VIE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Anti-CD19 Monoclonal Antibody Shows Positive Results in Myasthenia GravisOctober 16, 2024 | msn.comRGNX-Aktie erreicht 52-Wochen-Tief bei 9,28 US-DollarOctober 9, 2024 | de.investing.comREGENXBIO Inc.: REGENXBIO Appoints Mitchell Chan as Chief Financial OfficerSeptember 17, 2024 | finanznachrichten.deREGENXBIO ernennt Mitchell Chan zum neuen CFO in WachstumsphaseSeptember 17, 2024 | de.investing.comRegenxbio Names Mitchell Chan CFOSeptember 17, 2024 | markets.businessinsider.comFactor D Complement Inhibitor Market Will Witness Robust Growth with Emerging Therapies by 2034 | DelveInsightAugust 19, 2024 | finance.yahoo.com2024 Fire Awards: Meet this year's Ablaze honoreesAugust 16, 2024 | bizjournals.comFcRn Inhibitor Market is Predicted to Grow Rapidly During the Study Period (2020–2034) | DelveInsightApril 16, 2024 | finance.yahoo.comArriVent Wows Investors With Promising China-Developed Lung Cancer TreatmentJanuary 29, 2024 | benzinga.comArriVent Biopharma issues upsized $175M IPO, becomes region's first life sciences firm to go public in 2024January 27, 2024 | bizjournals.comArriVent Biopharma Seeks $100 Million IPO For Lung Cancer DrugJanuary 9, 2024 | seekingalpha.comArriVent BioPharma Files For IPOJanuary 5, 2024 | marketwatch.comMyasthenia Gravis Treatment Market Size, Share & Growth Analysis, [2028] | With CAGR of 7.5%December 6, 2023 | finance.yahoo.comGlobal CD19 Antibody Market and Clinical Pipeline Outlook and Competitive Landscape: Insight on 30 Key PlayersNovember 17, 2023 | benzinga.comGlobal CD19 Antibody Market Projected to Exceed $10 Billion by 2028, Driven by Promising Pipeline of TherapiesNovember 9, 2023 | uk.finance.yahoo.comGlobal CD19 Antibody Market Set to Surpass $10 Billion by 2028: A Revolutionary Era in ImmunotherapyNovember 3, 2023 | finance.yahoo.comAmgen’s layoffs won’t affect Horizon Therapeutics’ Rockville footprint — for nowOctober 25, 2023 | bizjournals.comEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical OfficerOctober 23, 2023 | finanznachrichten.deArgenx's 28% Surge & Promising Product Propel Investor Confidence (VIE)Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.September 25, 2023 | marketbeat.comInside 'Elon Musk': Wild details from revealing Walter Isaacson biographySeptember 20, 2023 | usatoday.comI’m an AI influencer: Followers crave my sexy snaps — but I don’t existJuly 26, 2023 | nypost.comN2023 Cutaneous Lupus Erythematosus (CLE) Treatment Market: Latest Technology Innovations and Comprehensive Growth Insights by 2031May 8, 2023 | marketwatch.comCutaneous Lupus Erythematosus (CLE) Treatment Market: Opportunities for Industry Expansion in 2030May 5, 2023 | marketwatch.com8-K: Horizon Therapeutics Public Ltd CoMay 5, 2023 | marketwatch.comArriVent Biopharma raises $155M in one of largest local funding rounds of 2023March 27, 2023 | bizjournals.comCutaneous Lupus Erythematosus (CLE) Treatment Market Application, Product, Sales and Forecast 2023-2028March 9, 2023 | marketwatch.comExploring the Challenges and Opportunities in the Cutaneous Lupus Erythematosus (CLE) Treatment Market (2023-2028)February 10, 2023 | marketwatch.comNeuromyelitis Optica Spectrum Disorder (NMOSD) Market is Set to Grow in forecast period 2029January 20, 2023 | marketwatch.comWith Horizon acquisition, Amgen would enter Montgomery County for the first time. Here’s what we know.December 13, 2022 | bizjournals.comHorizon Therapeutics spells out vision for Rockville R&D hubDecember 1, 2022 | bizjournals.comLife sciences firm MilliporeSigma doubling down on MoCo with $286M investmentNovember 16, 2022 | bizjournals.comSBI Holdings, Inc. (SBHGF) Q2 2023 Earnings Call TranscriptNovember 15, 2022 | seekingalpha.comWhy Horizon Therapeutics' Shares Rose 11.32% on WednesdayNovember 2, 2022 | msn.comCutaneous Lupus Erythematosus (CLE) Treatment Market Size, Sales, CAGR And Competition Data from 2022 To 2028October 21, 2022 | marketwatch.comAlpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial ResultsAugust 11, 2022 | nz.finance.yahoo.comViela Bio, Inc. NewsAugust 2, 2022 | thestreet.comHorizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven GrowthJuly 31, 2022 | seekingalpha.comAlpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of DirectorsJuly 19, 2022 | apnews.comACANbridge Appoints Industry Leader Edward Hu to the BoardJuly 5, 2022 | nz.finance.yahoo.comMyasthenia Gravis Treatment Market Size [2022-2029]: $2.03 Billion by 2028 at CAGR of 7.5%May 26, 2022 | ca.finance.yahoo.comHorizon: For Those Who DareMay 9, 2022 | seekingalpha.comImprove Your Portfolio’s Health By Investing In Health Care StocksApril 13, 2022 | forbes.comHorizon Therapeutics plc Reports Fourth-Quarter 2021 and Full-Year 2021 Financial Results; Announces Full-Year 2022 GuidanceMarch 1, 2022 | benzinga.comMyasthenia Gravis Treatment Market Size [2022-2028] worth USD 2.03 billion | Exhibit a CAGR of 7.5%February 28, 2022 | finance.yahoo.comHansoh Pharmaceutical Group Co Ltd (3692)February 26, 2022 | investing.comArriVent Biopharma hits key milestones, triggers additional $69M investmentFebruary 15, 2022 | bizjournals.comSystemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsightFebruary 9, 2022 | finance.yahoo.comHorizon Therapeutics signs lease for big expansion in Montgomery CountyJanuary 7, 2022 | bizjournals.comDublin biotech signs lease for big expansion in MarylandJanuary 7, 2022 | bizjournals.comViela Bio Inc (VIE)January 5, 2022 | investing.com Get Viela Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for VIE and its competitors with MarketBeat's FREE daily newsletter. Email Address VIE Media Mentions By Week VIE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIE News Sentiment▼0.000.45▲Average Medical News Sentiment VIE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIE Articles This Week▼00▲VIE Articles Average Week Get Viela Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for VIE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MorphoSys News Calliditas Therapeutics AB (publ) News Zymeworks News MBX Biosciences News Aerovate Therapeutics News Cybin News Virios Therapeutics News PyroGenesis Canada News OS Therapies News Actinium Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIE) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viela Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viela Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
